Vor pays RemeGen $10M for long-acting autoimmune drug successor
Vor Bio is paying RemeGen $10 million for rights to a long-acting successor to an autoimmune drug, adding the asset to its pipeline.
Clinical-stage biopharmaceutical company developing therapies for autoantibody-driven autoimmune disease. Its lead program, telitacicept, is a dual BAFF/APRIL inhibitor licensed from RemeGen and is in Phase 3 development for generalized myasthenia gravis and Sjogren's disease.
Vor Bio is paying RemeGen $10 million for rights to a long-acting successor to an autoimmune drug, adding the asset to its pipeline.
Chief Executive Officer and Chairman of the Board